Jul 15, 2026 01:29PM

Jul 15, 2026 10:18AM

Jul 15, 2026 09:51AM

Jul 15, 2026 09:21AM

May 21, 2026 10:23AM

Apr 21, 2026 08:37AM

Apr 21, 2026 06:52AM Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC

Mar 27, 2026 08:50AM

Mar 27, 2026 06:14AM

Mar 27, 2026 04:19AM

Mar 22, 2026 09:19PM

Mar 10, 2026 10:07PM

Mar 1, 2026 06:49PM

Feb 9, 2026 10:34PM Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China

Feb 6, 2026 01:04AM

Feb 5, 2026 08:31PM

Jan 25, 2026 11:52PM

Jan 25, 2026 08:37PM

Jan 12, 2026 06:50PM

Jan 5, 2026 07:43PM

Nov 26, 2025 06:03AM Eisai completes FDA submission for LEQEMBI subcutaneous starting dose

Nov 26, 2025 04:42AM

Nov 17, 2025 07:08AM

Oct 27, 2025 12:23AM

Oct 14, 2025 03:54AM

Oct 3, 2025 04:01AM

Sep 28, 2025 08:33PM

Sep 17, 2025 05:52AM Eisai's etalanetug receives FDA fast track designation for Alzheimer's

Sep 17, 2025 04:20AM

Sep 2, 2025 09:32PM

Sep 1, 2025 12:50AM

Aug 31, 2025 11:44PM

Jul 30, 2025 07:20PM

Jul 30, 2025 07:10PM

Jul 16, 2025 12:50AM Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab

May 21, 2025 01:00AM

Mar 4, 2025 02:22AM

Mar 2, 2025 10:53PM

Jan 27, 2025 06:46PM

Jan 14, 2025 07:03PM

Nov 14, 2024 11:31PM

Oct 31, 2024 11:56PM Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under

Oct 30, 2024 11:56PM

Sep 5, 2024 02:59AM

Aug 22, 2024 05:54AM

Aug 13, 2024 07:59PM

Aug 5, 2024 11:15PM

Jul 30, 2024 11:59PM

Jul 11, 2024 10:56PM "LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel

Jul 10, 2024 08:00PM

327,063 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All